TransCode Therapeutics Inc.

NASDAQ: RNAZ
Share price (10/20/25): $14.76
Market cap (10/20/25): $12.3 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024 – amended

ended 12/31/24 FY 2024

Late annual filing notification for FY 2024

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Exempt offering of securities

Initial registration of new securities

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

CK Life Sciences Intl (Holdings) Inc

Anson Funds Management LP

The Goldman Sachs Group Inc.

Tracy Thomas Joseph

Anson Funds Management LP

News Filter

Material Definitive Agreement, Financial Statements or Exhibits

Presents Preliminary Data From Its Completed Phase 1a Study With TTX-MC138 in Metastatic Disease at ESMO

Material Definitive Agreement, Financial Statements or Exhibits

Announces the Acquisition of Polynoma and a $25 Million Strategic Financing by a Subsidiary of CK Life Sciences to Form a First-In-Class Unique Immuno-Oncology and Metastatic Prevention Oncology Company

Material Definitive Agreement

Proxies Filter

Additional info about upcoming vote

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Scanned paper annual report submission

Notice of effectiveness